WO2012080747A3 - Anti-ageing agents - Google Patents

Anti-ageing agents Download PDF

Info

Publication number
WO2012080747A3
WO2012080747A3 PCT/GB2011/052498 GB2011052498W WO2012080747A3 WO 2012080747 A3 WO2012080747 A3 WO 2012080747A3 GB 2011052498 W GB2011052498 W GB 2011052498W WO 2012080747 A3 WO2012080747 A3 WO 2012080747A3
Authority
WO
WIPO (PCT)
Prior art keywords
ageing
materials
combination
relates
identifying
Prior art date
Application number
PCT/GB2011/052498
Other languages
French (fr)
Other versions
WO2012080747A2 (en
Inventor
Abigail Kate Langton
Christopher Ernest Maitland Griffiths
Michael John Sherratt
Rachel Elizabeth Beatrice Watson
Neil Kerslake Gibbs
Original Assignee
The University Of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Manchester filed Critical The University Of Manchester
Priority to GB1312511.7A priority Critical patent/GB2500549A/en
Publication of WO2012080747A2 publication Critical patent/WO2012080747A2/en
Publication of WO2012080747A3 publication Critical patent/WO2012080747A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7042—Aging, e.g. cellular aging

Abstract

This invention relates to a method for identifying an anti-ageing agent for use in skincare compositions, by determining the ability of a material or a combination of materials to modulate the expression of molecules associated with microfibril or elastic fibres. More specifically, the invention relates to a method for identifying an anti-ageing agent by determining the ability of a material or combination of materials to downregulate LOXL-1 expression. The invention also relates to methods for assessing the anti-ageing effect of a material or combination of materials on the skin, anti-ageing agents identified by such methods, and compositions containing them.
PCT/GB2011/052498 2010-12-17 2011-12-16 Anti-ageing agents WO2012080747A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1312511.7A GB2500549A (en) 2010-12-17 2011-12-16 Anti-ageing agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201021457A GB201021457D0 (en) 2010-12-17 2010-12-17 Anti-ageing agents
GB1021457.5 2010-12-17

Publications (2)

Publication Number Publication Date
WO2012080747A2 WO2012080747A2 (en) 2012-06-21
WO2012080747A3 true WO2012080747A3 (en) 2013-08-22

Family

ID=43598573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/052498 WO2012080747A2 (en) 2010-12-17 2011-12-16 Anti-ageing agents

Country Status (2)

Country Link
GB (2) GB201021457D0 (en)
WO (1) WO2012080747A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2402676A (en) * 2003-06-13 2004-12-15 Coletica Use of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of elastic fibres
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2008152656A2 (en) * 2007-06-13 2008-12-18 Decode Genetics Ehf Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009079126A1 (en) * 2007-12-19 2009-06-25 Avon Products, Inc. Topical compositions comprising non-proteogenic amino acids and methods of treating skin
WO2009085443A1 (en) * 2007-12-21 2009-07-09 Avon Products, Inc. Topical compositions containing desthiobiotin and its derivatives and a method of treating skin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2402676A (en) * 2003-06-13 2004-12-15 Coletica Use of the lysyl oxidase-like (LOXL) enzyme to stimulate formation of elastic fibres
WO2005069975A2 (en) * 2004-01-23 2005-08-04 Massachusetts Eye & Ear Infirmary Lysyl oxidase-like 1 (loxl1) and elastogenesis
US20060134172A1 (en) * 2004-12-21 2006-06-22 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (LOX) and LOX-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2008152656A2 (en) * 2007-06-13 2008-12-18 Decode Genetics Ehf Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma
WO2009079126A1 (en) * 2007-12-19 2009-06-25 Avon Products, Inc. Topical compositions comprising non-proteogenic amino acids and methods of treating skin
WO2009085443A1 (en) * 2007-12-21 2009-07-09 Avon Products, Inc. Topical compositions containing desthiobiotin and its derivatives and a method of treating skin

Also Published As

Publication number Publication date
GB201021457D0 (en) 2011-02-02
WO2012080747A2 (en) 2012-06-21
GB2500549A (en) 2013-09-25
GB201312511D0 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
WO2012116081A3 (en) Methods for identifying cosmetic agents for skin care compositions
BR112012019693A2 (en) antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use for them.
FR2964565B1 (en) COSMETIC COMPOSITION COMPRISING A FIXING POLYMER AND ANTIPELLICULAR AGENT
MX2013014544A (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy.
CR20140529A (en) ANTIBODIES AND IMMUNOCATE PLAYS AGAINST LY6E AND METHODS OF USE
BR112014000864A2 (en) nanocellulose composition, nanocellulose material and nanocellulose containing product
BR112014026755A2 (en) claudin 18.2 antibodies useful in cancer diagnosis
UA110470C2 (en) Antidote of anticoagulant
EP3995142A3 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
BR112014002769A2 (en) depilatory method and kit
BR112014026740A2 (en) antibody, composition, methods for treating a mammal and for providing an enhanced adcc antibody, and use of an antibody
MX365321B (en) Methods for treating neutropenia using retinoid agonists.
FR2976799B1 (en) COSMETIC COMPOSITION COMPRISING AT LEAST ONE PARTICULAR AMPHOTERIC POLYMER AND ANTIPELLICULAR AGENT.
NZ701463A (en) Anti-phytopathogenic composition
EP3622069A4 (en) Compositions and methods for loading extracellular vesicles with chemical and biological agents/molecules
TR201909824T4 (en) Bushing mechanisms and related methods.
NZ592994A (en) Diagnostic test for Streptococcus equi comprising assessing the presence or absence of the S. equi eqbE gene
BR112012021411A2 (en) braf mutations that confer resistance to braf inhibitors.
BR112014001066A2 (en) botulinum toxins for use in a method for treating adipose deposits
BRPI0912532A2 (en) method and device for treating a surface of a fiber composite material
BR112013021035A2 (en) improved soft tissue replacement compositions and methods
WO2012080747A3 (en) Anti-ageing agents
WO2012142256A3 (en) Modulators of mitochondrial protein import
GB2494570A (en) Anti-ageing agents
WO2011140334A3 (en) Compounds, methods of making or identifying compounds, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808697

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 1312511

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20111216

WWE Wipo information: entry into national phase

Ref document number: 1312511.7

Country of ref document: GB

122 Ep: pct application non-entry in european phase

Ref document number: 11808697

Country of ref document: EP

Kind code of ref document: A2

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref country code: GB